Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A new dose-finding design for bivariate outcomes.

Anastasia Ivanova1

  • 1Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. aivanova@bios.unc.edu

Biometrics
|February 19, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Competing-triggering effect models for multitype recurrent event data.

Biometrics·2026
Same author

Dynamic borrowing methods for basket trials with order restrictions.

Journal of biopharmaceutical statistics·2026
Same author

PrecISE-a biomarker-stratified adaptive trial of 5 interventions in severe asthma: Final protocol and the baseline cohort.

The Journal of allergy and clinical immunology·2026
Same author

Design characteristics of sequential multiple assignment randomised trials (SMARTs) for human health: a scoping review of studies between 2009 and 2024.

BMJ open·2025
Same author

Prediction of transition probabilities in multi-state models with nested case-control data.

Biometrics·2025
Same author

Dynamic prediction by landmarking with data from cohort subsampling designs.

Statistical methods in medical research·2025
Same journal

Fast penalized generalized estimating equations for large longitudinal functional datasets.

Biometrics·2026
Same journal

Causally-interpretable random-effects meta-analysis.

Biometrics·2026
Same journal

Statistical inference for mean function of partially observed functional time series.

Biometrics·2026
Same journal

Subgroup identification via Interaction Tree and Mixed Model for Repeated Measures with application to Alzheimer's disease.

Biometrics·2026
Same journal

Finite mixtures of linear quantile regressions with concomitant variables: a solution to endogeneity in longitudinal data modeling.

Biometrics·2026
Same journal

Discussion on "INTACT: a method for integration of longitudinal physical activity data from multiple sources" by Jingru Zhang, Erjia Cui, Hongzhe Li, and Haochang Shou.

Biometrics·2026
See all related articles

This study introduces a new sequential design for drug dose-finding trials. It aims to assign more patients near the optimal safe dose, balancing efficacy and toxicity.

Area of Science:

  • Clinical Trials
  • Pharmacology
  • Biostatistics

Background:

  • Drug development faces challenges with early treatment termination due to toxicity before therapeutic response.
  • Identifying optimal drug doses requires balancing efficacy and safety, considering outcomes like toxicity, response without toxicity, and no response.
  • The optimal safe dose maximizes response probability while keeping toxicity below a maximum tolerable level.

Purpose of the Study:

  • To present a novel sequential design for dose-finding trials.
  • To maximize patient allocation in the vicinity of the optimal safe dose.
  • To improve the efficiency of identifying effective and safe drug dosages.

Main Methods:

  • Development of a new sequential design for clinical trials.

Related Experiment Videos

  • Focus on dose-finding studies with binary outcomes (response and toxicity).
  • Methodology designed to center patient assignments around the optimal safe dose.

    • Main Results:

    • The proposed design aims to increase the number of subjects treated near the optimal safe dose.
    • This approach enhances the precision in identifying the most beneficial and least toxic drug levels.
    • The design addresses the challenge of early treatment discontinuation due to adverse events.

    Conclusions:

    • The novel sequential design offers an improved strategy for dose-finding trials.
    • It enhances patient safety by focusing on optimal safe doses.
    • This method contributes to more efficient drug development by optimizing dose selection.